Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/27750
Title: | Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers |
Authors: | Frisoni, Giovanni B. Boccardi, Marina Barkhof, Frederik Blennow, Kaj Cappa, Stefano Chiotis, Konstantinos Demonet, Jean-Francois Garibotto, Valentina Giannakopoulos, Panteleimon Gietl, Anton Hansson, Oskar Herholz, Karl Jack, Clifford R. Nobili, Flavio Nordberg, Agneta Snyder, Heather M. Kate, Mara Ten Varrone, Andrea Albanese, Emiliano Becker, Stefanie Bossuyt, Patrick Carrillo, Maria C. Cerami, Chiara Dubois, Bruno Gallo, Valentina Giacobini, Ezio Gold, Gabriel Hurst, Samia Lonneborg, Anders Lovblad, Karl-Olof Mattsson, Niklas Molinuevo, Jose-Luis Monsch, Andreas U. Mosimann, Urs Padovani, Alessandro Picco, Agnese Porteri, Corinna Ratib, Osman Saint-Aubert, Laure Scerri, Charles Scheltens, Philip Schott, Jonathan M. Sonni, Ida Teipel, Stefan Vineis, Paolo Visser, Pieter Jelle Yasui, Yutaka Winblad, Bengt |
Keywords: | Alzheimer's disease Biomarkers Early diagnosis Humans Validation studies as topic Neuropsychology Tomography, Emission Cerebrospinal fluid proteins |
Issue Date: | 2017 |
Publisher: | The Lancet Publishing Group |
Citation: | Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K.,… Winblad, B. (2017). Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. The Lancet Neurology, 16(8), 661-676. |
Abstract: | The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics. |
URI: | https://www.um.edu.mt/library/oar//handle/123456789/27750 |
Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Strategic_roadmap_for_an_early_diagnosis_of_Alzheimer's_disease_2017.pdf Restricted Access | 439.64 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.